Artia Global Partners LP purchased a new position in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 2,210,852 shares of the company's stock, valued at approximately $41,232,000. Trevi Therapeutics comprises approximately 7.6% of Artia Global Partners LP's investment portfolio, making the stock its 3rd biggest holding. Artia Global Partners LP owned approximately 1.55% of Trevi Therapeutics as of its most recent SEC filing.
Other institutional investors have also added to or reduced their stakes in the company. Hilton Head Capital Partners LLC boosted its stake in shares of Trevi Therapeutics by 32.6% in the 1st quarter. Hilton Head Capital Partners LLC now owns 4,250 shares of the company's stock worth $51,000 after buying an additional 1,044 shares during the last quarter. AlphaCentric Advisors LLC raised its stake in shares of Trevi Therapeutics by 5.7% during the 1st quarter. AlphaCentric Advisors LLC now owns 23,970 shares of the company's stock worth $286,000 after purchasing an additional 1,303 shares during the period. Kennedy Capital Management LLC raised its stake in shares of Trevi Therapeutics by 2.4% during the 4th quarter. Kennedy Capital Management LLC now owns 56,269 shares of the company's stock worth $704,000 after purchasing an additional 1,336 shares during the period. Oppenheimer & Co. Inc. boosted its holdings in shares of Trevi Therapeutics by 2.1% in the 4th quarter. Oppenheimer & Co. Inc. now owns 100,698 shares of the company's stock worth $1,261,000 after buying an additional 2,030 shares during the last quarter. Finally, California State Teachers Retirement System boosted its holdings in shares of Trevi Therapeutics by 2.6% in the 4th quarter. California State Teachers Retirement System now owns 83,788 shares of the company's stock worth $1,049,000 after buying an additional 2,091 shares during the last quarter. 95.76% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
Several brokerages have commented on TRVI. Wall Street Zen lowered shares of Trevi Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, July 25th. HC Wainwright raised their price target on shares of Trevi Therapeutics from $21.00 to $24.00 and gave the stock a "buy" rating in a research note on Monday, July 20th. Oppenheimer lifted their price target on shares of Trevi Therapeutics from $24.00 to $25.00 and gave the stock an "outperform" rating in a report on Friday, August 7th. Morgan Stanley reaffirmed an "overweight" rating and issued a $23.00 price target on shares of Trevi Therapeutics in a report on Friday, August 7th. Finally, JonesTrading upped their price objective on Trevi Therapeutics from $24.00 to $28.00 and gave the company a "buy" rating in a research note on Friday, August 14th. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, Trevi Therapeutics currently has a consensus rating of "Buy" and a consensus price target of $27.08.
Read Our Latest Research Report on Trevi Therapeutics
Trevi Therapeutics Trading Down 0.2%
Trevi Therapeutics stock opened at $17.92 on Thursday. The firm's 50 day simple moving average is $18.04 and its 200 day simple moving average is $14.71. The firm has a market capitalization of $2.55 billion, a PE ratio of -52.71 and a beta of 1.03. Trevi Therapeutics, Inc. has a 1-year low of $6.93 and a 1-year high of $20.22.
Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.11) EPS for the quarter, meeting the consensus estimate of ($0.11). Research analysts forecast that Trevi Therapeutics, Inc. will post -0.48 earnings per share for the current year.
Trevi Therapeutics Company Profile
(
Free Report)
Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.
Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.
Featured Articles
Want to see what other hedge funds are holding TRVI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Trevi Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Trevi Therapeutics wasn't on the list.
While Trevi Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
